Patents by Inventor Bong Yong Lee

Bong Yong Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10981917
    Abstract: The present invention relates to a heterocyclic compound represented by Chemical Formula 1 that can be used for the prevention or treatment of diseases caused by abnormality in a PRS (prolyl-tRNA synthetase) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: April 20, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Bong-Yong Lee, Min-Jae Cho, Hyung-Geun Lee, Myung-gi Jung, Yunju Oh
  • Publication number: 20200388629
    Abstract: A semiconductor device including a substrate; a lower structure including a sealing layer on the substrate and a support layer on the sealing layer, the sealing layer and the support layer both including a semiconductor material; a mold structure on the lower structure and having an interlayer insulating film and a conductive film alternately stacked therein; a channel hole penetrating the mold structure; a channel structure extending along sidewalls of the channel hole; an isolation trench penetrating the mold structure and extending into the lower structure; and a poly liner extending along sidewalls of the isolation trench, the poly liner being connected to the lower structure and including the semiconductor material.
    Type: Application
    Filed: December 3, 2019
    Publication date: December 10, 2020
    Inventors: Bong Yong LEE, Tae Hun KIM, Min Kyung BAE
  • Patent number: 10770477
    Abstract: A vertical semiconductor device includes a plurality of channel connection patterns, a lower insulation layer, a supporting layer, a stacked structure, and a channel structure. The channel connection patterns, on which the lower insulation layer is formed, contact a substrate. The supporting layer is formed on the lower insulation layer to be spaced apart from the channel connection patterns, and includes polysilicon doped with impurities. The stacked structure is formed on the supporting layer, and includes insulation layers and gate electrodes to form a memory cell string. The channel structure passes through the stacked structure, the supporting layer and the lower insulation layer, and includes a charge storage structure and a channel which contacts the channel connection patterns. The charge storage structure and the channel face the gate electrodes and the supporting layer. The supporting layer serves as a gate of a gate induced drain leakage (GIDL) transistor.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: September 8, 2020
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Bong-Yong Lee, Tae-Hun Kim, Min-Kyung Bae, Myung-Hun Woo
  • Patent number: 10696960
    Abstract: A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: June 30, 2020
    Assignee: TiumBio Co., Ltd.
    Inventors: In-Young Song, Hun-Taek Kim, Bong-Yong Lee, Mahn-Hoon Park, Ho-Soon Lee, Yun Jung Lim, Ji-Hye Lee, Seo Yeon Son, Min-Sun Kim
  • Publication number: 20200144285
    Abstract: A vertical semiconductor device includes a plurality of channel connection patterns, a lower insulation layer, a supporting layer, a stacked structure, and a channel structure. The channel connection patterns, on which the lower insulation layer is formed, contact a substrate. The supporting layer is formed on the lower insulation layer to be spaced apart from the channel connection patterns, and includes polysilicon doped with impurities. The stacked structure is formed on the supporting layer, and includes insulation layers and gate electrodes to form a memory cell string. The channel structure passes through the stacked structure, the supporting layer and the lower insulation layer, and includes a charge storage structure and a channel which contacts the channel connection patterns. The charge storage structure and the channel face the gate electrodes and the supporting layer. The supporting layer serves as a gate of a gate induced drain leakage (GIDL) transistor.
    Type: Application
    Filed: May 2, 2019
    Publication date: May 7, 2020
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Bong-Yong LEE, Tae-Hun KIM, Min-Kyung BAE, Myung-Hun WOO
  • Publication number: 20190359617
    Abstract: The present invention relates to a heterocyclic compound represented by Chemical Formula 1 that can be used for the prevention or treatment of diseases caused by abnormality in a PRS (prolyl-tRNA synthetase) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: February 7, 2018
    Publication date: November 28, 2019
    Inventors: Bong-Yong Lee, Min-Jae Cho, Hyung-Geun Lee, Myung-gi Jung, Yunju Oh
  • Patent number: 10155763
    Abstract: The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-? (TGF-?) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: December 18, 2018
    Assignee: TIUMBIO CO., LTD.
    Inventors: Ju Young Lee, Keun-Ho Ryu, Jae-Sun Kim, Yong-Hyuk Kim, Dong-Chul Shin, Bong-yong Lee, Sang-hwan Kang, Hyun-Jung Lee, Hoechul Jung, Young Ah Shin, Euisun Park, Jaeseung Ahn, Hun-Taek Kim, Je Ho Ryu
  • Patent number: 10011586
    Abstract: The present invention relates to a heterocyclic compound having a novel structure that can be used in the prevention or treatment of diseases caused by abnormality in a PRS (prolyl-tRNA synthetase) activity, a method for preparing the same, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: July 3, 2018
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Joon Seok Park, Youn Jung Yoon, Min Jae Cho, Ho Bin Lee, Ja Kyung Yoo, Bong Yong Lee
  • Patent number: 9960250
    Abstract: Provided are a power device having an improved field stop layer and a method of manufacturing the same. The method can include performing a first ion implant process by implanting impurity ions of a first conductive type into a front surface of a semiconductor substrate to form an implanted field stop layer where the semiconductor substrate is the first conductive type. The method can include performing a second ion implant process by implanting impurity ions of the first conductive type into a first part of the implanted field stop layer such that an impurity concentration of the first part of the implanted field stop layer is higher than an impurity concentration of a second part of the implanted field stop layer.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 1, 2018
    Assignee: Semiconductor Components Industries LLC
    Inventors: Kyu-hyun Lee, Young-chul Kim, Kyeong-seok Park, Bong-yong Lee, Young-chul Choi
  • Publication number: 20180044322
    Abstract: The present invention relates to a heterocyclic compound having a novel structure that can be used in the prevention or treatment of diseases caused by abnormality in a PRS (prolyl-tRNA synthetase) activity, a method for preparing the same, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: June 7, 2016
    Publication date: February 15, 2018
    Inventors: Joon Seok Park, Youn Jung Yoon, Min Jae Cho, Ho Bin Lee, Ja Kyung Yoo, Bong Yong Lee
  • Publication number: 20170243951
    Abstract: Provided are a power device having an improved field stop layer and a method of manufacturing the same. The method can include performing a first ion implant process by implanting impurity ions of a first conductive type into a front surface of a semiconductor substrate to form an implanted field stop layer where the semiconductor substrate is the first conductive type. The method can include performing a second ion implant process by implanting impurity ions of the first conductive type into a first part of the implanted field stop layer such that an impurity concentration of the first part of the implanted field stop layer is higher than an impurity concentration of a second part of the implanted field stop layer.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Applicant: FAIRCHILD KOREA SEMICONDUCTOR LTD.
    Inventors: Kyu-hyun LEE, Young-chul KIM, Kyeong-seok PARK, Bong-yong LEE, Young-chul CHOI
  • Publication number: 20170224660
    Abstract: The present invention provides a process for preparing an ertapenem-containing lyophilized formulation, comprising the use of hydroxypropyl p-cyclodextrin as both a cryoprotective agent and a stabilizing agent.
    Type: Application
    Filed: July 28, 2015
    Publication date: August 10, 2017
    Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Bong-Yong LEE, Hee-Kyoon YOON, Wol-Young KIM, Jeong-Taek SHIN
  • Patent number: 9717708
    Abstract: The present invention provides a process for preparing an ertapenem-containing lyophilized formulation, comprising the use of hydroxypropyl ?-cyclodextrin as both a cryoprotective agent and a stabilizing agent.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: August 1, 2017
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Bong-Yong Lee, Hee-Kyoon Yoon, Wol-Young Kim, Jeong-Taek Shin
  • Patent number: 9685335
    Abstract: Provided are a power device having an improved field stop layer and a method of manufacturing the same. The power device includes: a first field stop layer formed of a semiconductor substrate and of a first conductive type; a second field stop layer formed on the first field stop layer and of the first conductive type, the second field stop layer having a region with an impurity concentration higher than the first field stop layer; a drift region formed on the second field stop layer and of the first conductive type, the drift region having an impurity concentration lower than the first field stop layer; a plurality of power device cells formed on the drift region; and a collector region formed below the first field stop layer, wherein the second field stop layer includes a first region having a first impurity concentration and a second region having a second impurity concentration higher than the first impurity concentration.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: June 20, 2017
    Assignee: Fairchild Korea Semiconductor Ltd.
    Inventors: Kyu-hyun Lee, Young-chul Kim, Kyeong-seok Park, Bong-yong Lee, Young-chul Choi
  • Patent number: 9644197
    Abstract: A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: May 9, 2017
    Assignee: SK Chemicals Co., Ltd.
    Inventors: In-Young Song, Hun-Taek Kim, Bong-Yong Lee, Mahn-Hoon Park, Ho-Soon Lee, Yun Jung Lim, Ji-Hye Lee, Seo Yeon Son, Min-Sun Kim
  • Patent number: 9622986
    Abstract: Provided is a transdermal delivery system (for example, in the form of a patch) having a double-layer structure including a drug-containing matrix layer and an adhesive layer, wherein the drug-containing matrix layer is obtained by completely dissolving donepezil using a certain polymer and then formulating along with an adhesive; and a process for preparing the same. The transdermal delivery system according to the present invention does not show any crystallization of donepezil in the formulation, can release donepezil at a uniform rate for a long time, and can inhibit the release dumping phenomenon that occurs in a transdermal delivery system having a single-layer structure.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 18, 2017
    Assignee: SK Chemicals Co., Ltd.
    Inventors: Jong-Seob Im, Yong-Youn Hwang, Won-No Youn, Yeo-Jin Park, Hye-Min Kim, Joon-Gyo Oh, Hun-Taek Kim, Bong-Yong Lee
  • Patent number: 9617328
    Abstract: Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: April 11, 2017
    Assignee: SK CHEMICALS CO., LTD.
    Inventors: Min Sun Lee, Hun-Taek Kim, Bong-yong Lee, Mahn Hoon Park, Yun Jung Lim
  • Patent number: 9481684
    Abstract: Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: November 1, 2016
    Assignee: SK CHEMICALS CO., LTD.
    Inventors: Seon-Mi Kim, Jae-Sun Kim, Minhee Lee, So-young Lee, Bong-yong Lee, Young-Ah Shin, Euisun Park, Jung A Lee, Min-Young Han, Jaeseung Ahn, Taekyung Yoo, Hun-Taek Kim
  • Patent number: 9447383
    Abstract: Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: September 20, 2016
    Assignee: SK Chemicals Co., Ltd.
    Inventors: Yong Wook Park, Kun Se Lee, Bong-Yong Lee, Mahnhoon Park, Hun Kim, Yun-Hee Kim, Su-Jeen Lee
  • Publication number: 20160194622
    Abstract: A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.
    Type: Application
    Filed: March 25, 2016
    Publication date: July 7, 2016
    Inventors: In-Young Song, Hun-Taek Kim, Bong-Yong Lee, Mahn-Hoon Park, Ho-Soon Lee, Yun Jung Lim, Ji-Hye Lee, Seo Yeon Son, Min-Sun Kim